PharminoGen has presented prazole-carboxamide derivatives acting as cannabinoid CB1 receptor antagonists reported to be useful for the treatment of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, dyslipidemia and diabetes.

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the intestinal tract that often causes the development of colorectal cancer (CRC).

Viking Therapeutics has divulged dual agonists of GLP-1 and glucose-dependent insulinotropic receptor (GDIR) reported to be useful for the treatment of nonalcoholic fatty liver disease (NAFLD).

Sunshine Lake Pharma has synthesized amide pyrrole compounds reported to be useful for the treatment of liver cancer, cirrhosis and hepatitis B virus (HBV) infection.

Apeloa Pharmaceutical and Hangzhou Apeloa Medicine Research Institute have described new N-(benzoyl)-phenylalanine compounds acting as integrin alpha4beta7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease.

Secretion of gastric acid is tightly controlled by the neuroendocrine system of the stomach, formed by an interconnected network of nerves and different hormone-producing cell types, particularly G cells that release the hormone gastrin.

GentiBio announced that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).

Researchers at the Genome Institute of Singapore and affiliated organizations published results from a study that aimed to better understand the causes of pediatric syndrome with liver cirrhosis.

Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.